Should I buy or sell Cognition Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGTX shares. View CGTX analyst ratings or view top-rated stocks .

What is Cognition Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 12-month price objectives for Cognition Therapeutics' shares. Their CGTX share price targets range from $5.00 to $9.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price. View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts .

How have CGTX shares performed in 2024?

Cognition Therapeutics' stock was trading at $1.85 at the beginning of the year. Since then, CGTX stock has decreased by 0.5% and is now trading at $1.84. View the best growth stocks for 2024 here .

Are investors shorting Cognition Therapeutics?

Cognition Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 150,200 shares, a decrease of 34.2% from the March 15th total of 228,100 shares. Based on an average trading volume of 204,700 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's shares are sold short. View Cognition Therapeutics' Short Interest .

When is Cognition Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CGTX earnings forecast .

How were Cognition Therapeutics' earnings last quarter?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.11.

When did Cognition Therapeutics IPO?

Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.

How do I buy shares of Cognition Therapeutics?

Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CGTX

Cognition Therapeutics (CGTX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free CGTX Stock Alerts

$1.84

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.79
▼
$1.89
50-Day Range: $1.78
▼
$2.18
52-Week Range: $0.90
▼
$3.49

Volume: 116,807 shs
Average Volume: 133,800 shs
Market Capitalization: $71.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.67

Get Cognition Therapeutics alerts:

Cognition Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 262.3% Upside
$6.67 Price Target
Short Interest: Healthy
0.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$9,975 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.98) to ($1.38) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.93 out of 5 stars

Medical Sector

251st out of 912 stocks

Biological Products, Except Diagnostic Industry

36th out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Cognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.53% of the float of Cognition Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cognition Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cognition Therapeutics has recently decreased by 34.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cognition Therapeutics does not currently pay a dividend.
Dividend Growth
Cognition Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CGTX.

1.1

News and Social Media Coverage

Search Interest
5 people have searched for CGTX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
4 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cognition Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,975.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
23.80% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cognition Therapeutics are expected to decrease in the coming year, from ($0.98) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cognition Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cognition Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cognition Therapeutics has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cognition Therapeutics Stock (NASDAQ:CGTX)

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

CGTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGTX Stock News Headlines

April 2, 2024 | globenewswire.com

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

April 1, 2024 | finance.yahoo.com

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 1, 2024 | globenewswire.com

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

March 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trials

March 27, 2024 | finance.yahoo.com

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript

March 26, 2024 | globenewswire.com

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

March 26, 2024 | benzinga.com

A Preview Of Cognition Therapeutics's Earnings

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 15, 2024 | globenewswire.com

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

March 14, 2024 | globenewswire.com

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

March 12, 2024 | markets.businessinsider.com

Cognition Therapeutics Prices Public Offering Of About 6.57 Mln Shares At $1.75/shr

March 12, 2024 | msn.com

Cognition Therapeutics announces pricing of stock offering to raise $11.5M

March 11, 2024 | msn.com

Giants GM Joe Schoen swings big in trade, blockbuster contract for Panthers pass rusher Brian Burns while losing Xavier McKinney

March 11, 2024 | globenewswire.com

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

March 11, 2024 | globenewswire.com

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

March 6, 2024 | finance.yahoo.com

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

March 6, 2024 | globenewswire.com

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies

February 26, 2024 | globenewswire.com

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

February 22, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)

February 6, 2024 | finanznachrichten.de

Cognition Therapeutics, Inc.: New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

February 6, 2024 | finance.yahoo.com

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

February 1, 2024 | msn.com

Study suggests how cognitive behavioral therapy changes brain activity in children with anxiety

January 16, 2024 | finance.yahoo.com

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

January 8, 2024 | msn.com

Digital CBT intervention reduces anxiety and improves quality of life for pulmonary fibrosis patients

January 4, 2024 | finanznachrichten.de

Cognition Therapeutics, Inc.: Cognition Therapeutics CEO Issues Letter to Shareholders

January 4, 2024 | finance.yahoo.com

Cognition Therapeutics CEO Issues Letter to Shareholders

See More Headlines

Receive CGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CGTX
CUSIP: N/A
CIK: 1455365
Web: www.cogrx.com
Phone: 412-481-2210
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.67
High Stock Price Target: $9.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +262.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-25,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -83.48%
Return on Assets: -63.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.37
Quick Ratio: 3.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.76 per share
Price / Book: 2.42

Miscellaneous

Outstanding Shares: 39,000,000
Free Float: 29,718,000
Market Cap: $71.76 million
Optionable: Not Optionable
Beta: 1.63

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Ms. Lisa Ricciardi (Age 64)
CEO, President & Director
Comp: $794.04k
Dr. Anthony O. Caggiano M.D.
Ph.D., Chief Medical Officer and Head of R&D
Mr. John Brendan Doyle (Age 47)
Chief Financial Officer
Dr. Steven A. Weissman Ph.D.
VP & Head of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cognition Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGTX shares.
View CGTX analyst ratings or view top-rated stocks.
What is Cognition Therapeutics' stock price target for 2024?: 3 Wall Street analysts have issued 12-month price objectives for Cognition Therapeutics' shares. Their CGTX share price targets range from $5.00 to $9.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price.
View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts.
How have CGTX shares performed in 2024?: Cognition Therapeutics' stock was trading at $1.85 at the beginning of the year. Since then, CGTX stock has decreased by 0.5% and is now trading at $1.84.
View the best growth stocks for 2024 here.
Are investors shorting Cognition Therapeutics?: Cognition Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 150,200 shares, a decrease of 34.2% from the March 15th total of 228,100 shares. Based on an average trading volume of 204,700 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's shares are sold short.
View Cognition Therapeutics' Short Interest.

When is Cognition Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CGTX earnings forecast.
How were Cognition Therapeutics' earnings last quarter?: Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.11.
When did Cognition Therapeutics IPO?: Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at $11.00-$13.00 per share.
How do I buy shares of Cognition Therapeutics?: Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial